Alzheimer’s starts decades before memory loss — scientists are now trying to pinpoint the moment of no return
By the time someone forgets a name or gets lost on a familiar route, Alzheimer’s disease may have been quietly progressing in their brain for twenty or thirty years.
Alzheimer’s has long been framed as a disease of old age. But the biology gets started much earlier. Protein accumulations in the brain — particularly amyloid-beta and tau, two proteins that clump abnormally in Alzheimer’s — can be present for decades before a person notices any cognitive change. An analysis published in Science examines this timeline in detail and asks a pointed question: at what stage does intervention actually become futile?
That is not a rhetorical question. Most clinical trials for Alzheimer’s treatments have failed for decades, in part because they enrolled patients whose neurodegeneration — the progressive death of brain cells — was already far advanced. The damage, by then, was simply beyond reversal. New evidence suggests there is a specific window, somewhere between the first biological signs and the first cognitive complaints, where intervention is most likely to matter.
Localizing the tipping point
Researchers are now using advanced brain imaging and blood-based tests to detect the earliest signs of amyloid accumulation. A new generation of blood markers — particularly phospho-tau 217, a modified form of the tau protein detectable in blood years before clinical diagnosis — makes it possible to identify people in that critical phase well before any symptoms appear.
The Science analysis describes how the disease does not progress linearly. There are periods of relatively slow accumulation, followed by acceleration around certain biological thresholds. That acceleration appears to coincide with the point at which the brain exhausts its compensatory mechanisms — the reserve capacity that temporarily masks decline. Once past that threshold, deterioration speeds up considerably.
Early detection raises a harder question
Early detection brings not only medical but ethical complexity: what do you do with the knowledge that you are in an early stage of Alzheimer’s, when no proven cure currently exists? Newer drugs — including lecanemab and donanemab, which clear amyloid from the brain — have been approved in the United States and show for the first time some clinical effect in early-stage disease. But the benefits are modest, the side effects considerable, and access remains limited.
Tracking the turning point, as the Science piece puts it, is only step one. The next step — intervening effectively at the moment it still makes a difference — remains one of the most consequential unsolved problems in medicine.